Status epilepticus associated with dalfampridine in a patient with multiple sclerosis

Journal of Neuropsychiatry and Clinical Neurosciences

Volumn 24, Issue 4, 2012, Pages

  De Gusmao, Claudio M ^a   Ortega, Melissa R ^a   Wallace, Douglas M ^b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOPYRIDINE; ETIRACETAM; FOSPHENYTOIN SODIUM; LORAZEPAM; MORPHINE SULFATE; NATALIZUMAB; PROPOFOL; TIZANIDINE;

ADULT; ADVERSE OUTCOME; CANNABIS SMOKING; CASE REPORT; COCAINE DEPENDENCE; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ELECTROENCEPHALOGRAM; EMERGENCY CARE; EPILEPTIC STATE; HUMAN; IRRITABILITY; LETTER; MALE; MULTIPLE SCLEROSIS; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; URINALYSIS; WALKING SPEED; WHITE MATTER LESION;

EID: 84871349687     PISSN: 08950172     EISSN: 15457222     Source Type: Journal    
DOI: 10.1176/appi.neuropsych.11110338     Document Type: Letter

References (4)

1. JefferyDR, Pharr EP: Dalfampridine Sustained-Release for symptomatic improvement of walking speed in patients with multiple sclerosis. Core Evid 2010; 5:107-112; Dove Press; available at http://www.dovepress.com/coreevidence-journal
2. Goodman AD, Brown TR, Krupp LB, Fampridine MS-F203 Investigators, et al: Sustained-release oral fampridine in multiple sclerosis: a randomised, doubleblind, controlled trial. Lancet 2009; 373:732-738
3. Striano P, Orefice G, Brescia Morra V, et al: Epileptic seizures in multiple sclerosis: clinical and EEG correlations. Neurol Sci 2003; 24:322-328
4. Goodman AD, Brown TR, Edwards KR, MSF204 Investigators, et al: A Phase-3 trial of extended-release oral dalfampridine in multiple sclerosis. Ann Neurol 2010; 68:494-502